Selvita S.A. Stock price

Equities

SLV

PLSLVCR00029

Biotechnology & Medical Research

Market Closed - Warsaw S.E. 12:55:44 2024-03-28 pm EDT 5-day change 1st Jan Change
66.7 PLN +6.55% Intraday chart for Selvita S.A. +6.55% +14.02%
Sales 2023 * 359M 89.76M Sales 2024 * 424M 106M Capitalization 1.15B 287M
Net income 2023 * 13M 3.25M Net income 2024 * 31M 7.75M EV / Sales 2023 * 3.66 x
Net Debt 2023 * 167M 41.66M Net Debt 2024 * 205M 51.2M EV / Sales 2024 * 3.19 x
P/E ratio 2023 *
110 x
P/E ratio 2024 *
35.2 x
Employees 404
Yield 2023 *
-
Yield 2024 *
-
Free-Float 78.23%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.44%
1 week+1.44%
Current month+8.18%
1 month+7.81%
3 months+5.83%
6 months+6.37%
Current year+8.55%
More quotes
1 week
61.10
Extreme 61.1
63.50
1 month
57.00
Extreme 57
63.60
Current year
57.00
Extreme 57
63.80
1 year
55.40
Extreme 55.4
83.50
3 years
54.60
Extreme 54.6
91.60
5 years
18.00
Extreme 18
91.60
10 years
18.00
Extreme 18
91.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 07-08-31
Director of Finance/CFO - 19-07-31
Chief Operating Officer - 09-01-01
Members of the board TitleAgeSince
Director/Board Member 47 19-09-18
Director/Board Member - 19-09-18
Director/Board Member 72 -
More insiders
Date Price Change Volume
24-03-28 66.7 +6.55% 28 896
24-03-27 62.6 +2.29% 3,951
24-03-26 61.2 -0.97% 2,352
24-03-25 61.8 -0.96% 1,201
24-03-22 62.4 -0.32% 1,108

Delayed Quote Warsaw S.E., March 28, 2024 at 05:32 am EDT

More quotes
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
62.6 PLN
Average target price
71.58 PLN
Spread / Average Target
+14.35%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Selvita S.A. - Warsaw S.E.